Subjects with oral herpes lesions at the time of serum sampling had higherefficiency antibody (higher proportion of neutralizing antibody as determined by plaque reduction, compared with total antibody as detected by radioimmunoassay) to herpes simplex virus type 1 (HSV-1) than did subjects with no lesions at the time of serum sampling. These higher-efficiency sera also had higher antibody titers to structural components of herpes simplex virus type 1 than did the lowefficiency sera. Absorption of high-and low-efficiency sera with purified herpes simplex virus type 1 particles removed all neutralizing antibody but not all antibody detected by radioimmunoassay. High-efficiency serum was depleted of more antibody to particulate antigen than was the low-efficiency serum, indicating that the high-efficiency serum contained a higher proportion of antibody to the virus particle.
Subjects with oral herpes lesions at the time of serum sampling had higherefficiency antibody (higher proportion of neutralizing antibody as determined by plaque reduction, compared with total antibody as detected by radioimmunoassay) to herpes simplex virus type 1 (HSV-1) than did subjects with no lesions at the time of serum sampling. These higher-efficiency sera also had higher antibody titers to structural components of herpes simplex virus type 1 than did the lowefficiency sera. Absorption of high-and low-efficiency sera with purified herpes simplex virus type 1 particles removed all neutralizing antibody but not all antibody detected by radioimmunoassay. High-efficiency serum was depleted of more antibody to particulate antigen than was the low-efficiency serum, indicating that the high-efficiency serum contained a higher proportion of antibody to the virus particle.
Infection with herpes simplex virus type 1 (HSV-1) commonly causes gingivostomatitis, pharyngitis, tonsilitis, fever blisters, kerato-conjunctivitis, skin and genital lesions, and, less frequently, meningitis and encephalitis. In populations living in low socioeconomic conditions, the peak incidence of infections occurs in children between 1 and 3 years of age (6, 9, 15, 16) . Although 80% of adults in the lower socioeconomic groups have HSV-1 antibodies, only 30 to 50% of adults in the higher socioeconomic groups have these antibodies (9) .
One of the characteristics ofherpesvirus infections is the ability of the virus to persist in a latent state, with recurrence of lesions induced by many stimuli including heat, ultraviolet light, menstruation, psychic stress, other infections, and immunosuppresive drugs. This recurrence takes place in the presence of high serum neutralizing antibody titers (2, 4, 5, 12) . Ship et al. (11) , in a study of students whose average age was 19 years, found that 40% of the total population had recurrent oral herpes lesions. Since the total number of individuals who had serum antibodies was much greater than the number of individuals who had recurrent lesions, certain factors protecting those without recurrences may be missing in those with recurrences. It is not known whether specific resistance is due primarily to: (i) antibody, (ii) cell-mediated immunity, (iii) complement or other innate mechanisms of immunity, (iv) unknown factors, or (v) any combination of the above.
The radioimmunoassay (RIA) probably measures antibodies to each of 50 or more different viral proteins produced by HSV-1 (17) . It is not known how much antibody measured by RIA is directed toward viral surface structures and is, therefore, responsible for neutralization. It is assumed that different subjects would have different concentrations of antibodies to viral structures, which may or may not be neutralizing, as well as to nonstructural viral antigens. It is possible that the difference in the ratio between neutralizing activity and total antibody (measured by RIA) might be related to the recurrence of oral herpes lesions.
The purpose of this investigation was to study serum HSV-1 antibodies in subjects with frequent oral lesions, compared to subjects with infrequent oral lesions. We wanted to determine whether there are differences in: (i) the ratio of neutralizing antibody, as determined by plaque reduction (PR), to total antibody (as detected by RIA); and (ii) the concentration of antibodies to HSV-1 structural components. MATERIALS Virus neutralization test system. Sera to be tested for neutralizing activity were heat inactivated at 560C for 30 min. Fresh frozen guinea pig serum, used as a source of complement, was added to the medium at a final dilution of 1:30. This complementmedium mixture was calculated to contain 36 to 48 C'H50 U/ml (1) and was used as diluent in the preparation of virus dilutions and further serum dilutions.
A 0.3-ml amount of HSV-1 virus dilution (grown in human fetal lung cells and previously calculated to produce approximately 100 plaques) was added to 0.3 ml of each serum dilution and incubated for 1 h at room temperature. The virus control consisted of equal parts of diluent and the working dilution of virus suspension. After removal of growth medium, 0.2 ml of each serum-virus mixture and diluent-virus mixture was added to duplicate human fetal lung cell cultures grown in 35-mm tissue culture plates. These plates were incubated and shaken at room temperature for 1 h. The inoculum was removed; 1 ml of medium was added to the plates which were incubated at room temperature for 1 h. The medium was removed and 2 ml of 1% immune serum globulin (Abbot-Gammar) in medium was added to each plate. Plates were incubated for 40 to 48 h at 370C. Culture medium was discarded, and plaques were stained with a 1:10 dilution of 1% crystal violet solution in water. Plaques were counted, and percent PR was calculated by use of the following formula: % PR = 100 -(average number of plaques, in serum dilution/average number of plaques, in virus control) x 100. The results were graphed, and the endpoint was determined as that dilution of serum which reduced the number of plaques by 50%. The titer is expressed as the reciprocal of the endpoint.
Preparation of RIA antigens. For crude HSV-1 antigen, human amnion cells were inoculated with HSV-1 and adsorbed for 1 h at room temperature. The inoculum was removed; the culture was refed with medium and incubated at 370C until a 4+ cytopathogenic effect was seen. Cells were scraped from the flask and centrifuged at 1,000 rpm for 3 min. The cells were washed twice in phosphate-buffered saline (PBS) and then frozen at -70°C. The pellet was thawed and suspended in 10 ml of PBS, and five aliquots of 2 ml each were prepared and frozen at -70°C. For use as antigen, 4 ml of PBS was added to one portion, and the mixture was treated in a sonicator (Heat Systems-Ultrasonics, Inc., Plainview, N.Y.) at a setting for 7 for 20 s. Uninoculated cell cultures treated the same way were used as control antigen. Capsid and envelope antigens were prepared as described elsewhere (3).
Chloramine T procedure for 125I labeling of antiglobulin. Rabbit antiserum to human globulin, purified by affinity chromatography, was labeled with '25I by the procedure of McConahey and Dixon (7).
The dilution used was determined by testing various dilutions of the labeled antiglobulin with constant amounts of other reagents in the test system. RIA procedure. For RIA, the method described previously by Smith et al. (13) and Patterson and Smith (10) was followed. The magnetic system of processing beads reported by Smith and Gehle (14) was used throughout all RIA procedures. Briefly, polycarbonate-coated beads were incubated with the appropriate antigen or control for 1 h at 4°C. The excess antigen solution was then removed; the sensitized beads were soaked in diluent (1% bovine serum albumin contained in a solution of PBS and 0.1% sodium azide) and then incubated overnight at 4°C in appropriate dilutions of sera. The beads were washed in water and incubated in "'2I-labeled rabbit antiserum to human globulin for 3 h at room temperature. The beads were again washed, placed in tubes and counted in a Packard Auto-Gamma counter. Specific counts for HSV antibody were determined by subtracting counts obtained with control antigen from counts obtained with viral antigen incubated with the same serum.
The endpoint of the titrations was considered either to be the dilution at which the counts of the test antigen were twice the control or at a number of specific counts. The method used will be noted for the individual experiment. The titer is the reciprocal of the endpoint.
Preparation and testing of sera absorbed with partially purified virus particles. A 1:400 dilution of a high-efficiency serum (one in which biologically active or neutralizing antibodies made up a high percentage of total antibodies) and a 1:50 dilution of a low-efficiency serum were made in diluent. For the high-efficiency serum, this was approximately 10 U of antibody, and for the low-efficiency serum (one in which biologically active or neutralizing antibodies made up a low percentage of total antibodies) this was approximately 2 U of antibody as calculated by the plaque reduction test. Increasing amounts of virus particle preparation, hereafter known as antigen, were added to the sera as shown in Table 1 . For the highefficiency serum, this gave a final dilution of 1:500, and for the low-efficiency serum this gave a final dilution of 1:62.5.
The tubes were then incubated at 37°C for 1 h with occasional shaking and then were placed at 4°C overnight on an aliquot mixer (Ames Co.). The treated sera were then centrifuged at 24,000 rpm for 1 h in a Beckman L2-65B ultracentrifuge. The supernatant fluid was removed, placed in tubes, capped, and submerged in a 56°C water bath for 30 min to inactivate any residual viral infectivity.
Each of the five tubes from each serum absorbed with various amounts of antigen was tested for HSV-1 antibodies by RIA and PR. In addition, high-and low-efficiency sera, either containing no antigen or exhaustively absorbed with antigen, were titrated by 
RESULTS
Analysis of neutralizing efficiency of HSV-1 antibodies. Sera from eight subjects with histories of frequent oral herpes lesions and sera from six subjects with histories of infrequent or rare lesions were tested for antibodies to HSV-1 by RIA and PR ( Table 2 ). All assays for RIA or PR were performed at the same time. Fold differences were calculated for each serum by dividing the RIA titer by the PR titer. The fold difference was used as an index of the "efficiency" of antibody; the lower the number (more neutralizing antibody in proportion to RIA antibody), the more efficient or effective the antibody was in its neutralizing activity. There was an efficiency range from very efficient (2.7; serum no. 2), to very inefficient (15; sera no. 13 and 14). In Table 3 , each serum was ranked by its index of efficiency and compared with the history of lesions of each subject and the presence of lesions at the time of sampling. These data indicated that there were large differences in the proportion of neutralizing antibodies to total measurable antibodies in the sera of different individuals. There was a correlation (P < 0.05 as determined by chi-square analysis with the Yates correction) between efficiency of antibody and the presence of lesions at the time of sampling.
Analysis of HSV-1-specific antibodies to structural antigens and total (structural and nonstructural) antigens. To determine whether efficiency of antibody was dependent on antibody titers to viral structural compo- The four subjects with high-efficiency antibody were having lesions at the time of sampling. Determination of relative amounts of antibodies to HSV-1 particle antigens versus total HSV-1 antibodies. The possibility that the difference between high-and low-efficiency sera might be due to the amount of antibodies directed against the whole viral particle was studied next. By treating a high-and a lowefficiency serum with these viral particles to remove antibodies directed against them and testing for HSV-1 antibodies, it might be possible to detect differences between high-and lowefficiency sera.
A high-efficiency serum was absorbed, at one time, to a constant level of HSV-1 antibody (RIA) with a total of 0.75 ml of concentrated partially purified HSV-1 (Fig. 1A) . Neutralizing antibody (63% reduction) was present in serum absorbed with 0.25 ml of antigen; absorption with 0.5 ml of antigen further removed neutralizing antibody to 39% PR; absorption with 0.75 ml or 1 ml of antigen completely removed neu- tralizing antibody (Fig. 1B) . Thus, all neutralizing antibody could be removed by absorption with HSV-1 particles, but not all RIA antibody could be so removed, indicating that some antibody was directed toward nonstructural antigens.
A low-efficiency serum was exhaustively absorbed (antibody detected by RIA) with 0.5 ml of antigen (Fig. 2A) . Absorption with 0.25 ml of antigen reduced neutralizing activity to 15%, whereas absorption with 0.50 ml or more removed this remaining activity (Fig. 2B) higher proportion of antibody to the particulate structural antigens than did the low-efficiency serum.
DISCUSSION
The term efficiency, when applied to HSV-1 antibodies in this study, indicates a relationship between the total amount of antibodies, detected by RIA, and neutralizing antibody, determined by the plaque reduction test. A relatively highefficiency serum was one in which neutralizing antibodies made up a higher percentage of the total antibodies. A lower-efficiency serum was one in which the neutralizing antibodies made up a smaller percentage of the total antibodies. When the ratios of total antibodies to neutralizing antibodies were calculated for sera from a number of subjects, it was clear that there was a wide range of efficiencies. The occurrence of more "efficient" antibody appeared to be linked to presence of lesions at the time of sampling.
The in vitro situation regarding neutralization may be quite different from the in vivo situation where large quantities of virus may be involved. Complement would be found in the in vivo situation, and therefore it was used in the in vitro assay.
Relatively high-and low-efficiency sera were studied to see if any differences could be detected in regard to antibodies to structural components of HSV-1. High-efficiency sera were found to have higher antibody titers to crude, envelope, and capsid antigens than did low-efficiency sera.
Absorption of both high-and low-efficiency sera with various amounts of purified HSV-1 particles removed all neutralizing activity, but not all antibodies detected by RIA could be so removed. These results could not be explained by the fact that the RIA is far more sensitive for detecting viral antibody than the neutralization test. This residual, unabsorbed antibody was probably directed toward nonstructural antigens and consisted of 15 to 28% of the total antibody. A high-efficiency serum, exhaustively absorbed with partially purified HSV-1 virions and compared with an unabsorbed preparation of the same serum, showed a 36-fold reduction in antibodies to total HSV-1 antigens, as compared with a 16-fold reduction in a low-efficiency serum treated the same way. Thus, high-efficiency serum can be depleted of a higher proportion of antibody to the particulate antigen than the lowefficiency serum, indicating that more of the high-efficiency serum was composed of antibody to virus particles.
Neutralizing activity is associated with antibodies to the viral envelope (8) . Since more neutralizing antibodies in proportion to total (RIA-detectable) antibodies is the criterion for a more efficient serum, high efficiency is due to increased antibodies to the envelope antigens produced during periods of lesion recurrence.
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